Relevant bibliographies by topics / Therapeutic peptide

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Therapeutic peptide'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Therapeutic peptide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Therapeutic peptide"

1

Preet, Payal. "PEPTIDES: A NEW THERAPEUTIC APPROACH." International Journal of Current Pharmaceutical Research 10, no. 2 (March 15, 2018): 29. http://dx.doi.org/10.22159/ijcpr.2018v10i2.25887.

Full text
Abstract:
Peptide therapeutics have played a notable role in medical practice since the advent of insulin therapy in the 1920s. Over 60 peptide drugs are approved in the United States and other major markets, and peptides continue to enter clinical development at a steady pace. Peptide drug discovery has diversified beyond its traditional focus on endogenous human peptides to include a broader range of structures identified from other natural sources or through medicinal chemistry efforts. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R and D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell-penetrating peptides, as well as peptide drug conjugates. In regards to patient compliance for drug delivery, oral drug delivery is generally the preferred route of administration. However, parental injection of peptide drugs has always been the primary method of peptide drug administration. Nevertheless, oral delivery of peptide drug presents a significant challenge due to the enzymatic degradation by enzymes in the GI tract and the poor penetration of the peptides across gastro-intestinal epithelium membranes, particularly for adults. Therefore, a novel peptide drug analogue or pro-drug that both protect peptide drugs from degradation by the enzymes in the GI tract that also improves its penetration across the intestinal epithelium membrane would greatly advance the development of peptide drugs as effective candidates for the treatment of various diseases.
APA, Harvard, Vancouver, ISO, and other styles
2

Fujita, Motomichi, Manabu Sasada, Takuya Iyoda, Satoshi Osada, Hiroaki Kodama, and Fumio Fukai. "Biofunctional Peptide FNIII14: Therapeutic Potential." Encyclopedia 1, no. 2 (April 8, 2021): 350–59. http://dx.doi.org/10.3390/encyclopedia1020029.

Full text
Abstract:
Biofunctional peptide FNIII14, which is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule, is capable of inhibiting cell adhesion to the extracellular matrix (ECM). This functional site is usually buried within the molecular structure of FN, but can be exposed by conformational changes and proteolytic cleavage. Peptide FNIII14 can induce a conformational change in β1-integrin from the active to the inactive form, causing functional inactivation. Based on this anti-adhesive activity, peptide FNIII14 exhibits therapeutic potential for several diseases such as metabolic diseases, organ fibrosis, and malignant tumors. Peptide FNIII14 blocks integrin-mediated signaling by a mechanism entirely distinct from that of conventional antagonisitic peptides, including Arg-Gly-Asp peptides that competitively inhibit the ECM binding of integrin.
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Yu P., and Quan Zou. "PPTPP: a novel therapeutic peptide prediction method using physicochemical property encoding and adaptive feature representation learning." Bioinformatics 36, no. 13 (April 29, 2020): 3982–87. http://dx.doi.org/10.1093/bioinformatics/btaa275.

Full text
Abstract:
Abstract Motivation Peptide is a promising candidate for therapeutic and diagnostic development due to its great physiological versatility and structural simplicity. Thus, identifying therapeutic peptides and investigating their properties are fundamentally important. As an inexpensive and fast approach, machine learning-based predictors have shown their strength in therapeutic peptide identification due to excellences in massive data processing. To date, no reported therapeutic peptide predictor can perform high-quality generic prediction and informative physicochemical properties (IPPs) identification simultaneously. Results In this work, Physicochemical Property-based Therapeutic Peptide Predictor (PPTPP), a Random Forest-based prediction method was presented to address this issue. A novel feature encoding and learning scheme were initiated to produce and rank physicochemical property-related features. Besides being capable of predicting multiple therapeutics peptides with high comparability to established predictors, the presented method is also able to identify peptides’ informative IPP. Results presented in this work not only illustrated the soundness of its working capacity but also demonstrated its potential for investigating other therapeutic peptides. Availability and implementation https://github.com/YPZ858/PPTPP. Supplementary information Supplementary data are available at Bioinformatics online.
APA, Harvard, Vancouver, ISO, and other styles
4

Karwal, Preeti, Ishwar Dutt Vats, Niharika Sinha, Anchal Singhal, Teena Sehgal, and Pratibha Kumari. "Therapeutic Applications of Peptides against Zika Virus: A Review." Current Medicinal Chemistry 27, no. 23 (July 1, 2020): 3906–23. http://dx.doi.org/10.2174/0929867326666190111115132.

Full text
Abstract:
Zika Virus (ZIKV) belongs to the class of flavivirus that can be transmitted by Aedes mosquitoes. The number of Zika virus caused cases of acute infections, neurological disorders and congenital microcephaly are rapidly growing and therefore, in 2016, the World Health Organization declared a global “Public Health Emergency of International Concern”. Anti-ZIKV therapeutic and vaccine development strategies are growing worldwide in recent years, however, no specific and safe treatment is available till date to save the human life. Currently, development of peptide therapeutics against ZIKV has attracted rising attention on account of their high safety concern and low development cost, in comparison to small therapeutic molecules and antibody-based anti-viral drugs. In present review, an overview of ZIKV inhibition by peptide-based inhibitors including E-protein derived peptides, antimicrobial peptides, frog skin peptides and probiotic peptides has been discussed. Peptides inhibitors have also been reported to act against NS5, NS2B-NS3 protease and proteasome in order to inhibit ZIKV infection. Recent advances in peptide-based therapeutics and vaccine have been reviewed and their future promise against ZIKV infections has been explored.
APA, Harvard, Vancouver, ISO, and other styles
5

Brockhoff, Warnholtz, and Münzel. "Atrial natriuretic peptides – diagnostic and therapeutic potential." Therapeutische Umschau 57, no. 5 (May 1, 2000): 305–12. http://dx.doi.org/10.1024/0040-5930.57.5.305.

Full text
Abstract:
Die Familie der natriuretischen Peptide besteht aus insgesamt drei Peptiden, die große Übereinstimmung in Bezug auf die Aminosäuresequenzen und eine Schleife in ihrer Struktur besitzen. Das Atriale Natriuretische Peptid (ANP) und das Brain Natriuretische Peptid (BNP) wirken diuretisch, natriuretisch und vasodilatierend und besitzen wichtige antagonisierende Wirkungen in Bezug auf das Renin-Angiotensin-System. Das CNP hingegen ist weit weniger gut charakterisiert und besitzt im Gegensatz zu ANP und BNP nur vasodilatierende und keine diuretischen Eigenschaften. Die Plasmaspiegel von ANP und BNP sind bei Patienten mit instabiler AP-Symptomatik, akutem Myokardinfarkt und chronischer Herzinsuffizienz erhöht. Aufgrund der bisherigen Untersuchungen besitzt das BNP und nicht das ANP möglicherweise eine gewisse Bedeutung als Prognosefaktor bei Patienten nach Herzinfarkt und bei Patienten mit Herzinsuffizienz. Während die Peptide selbst nur eine geringe Bedeutung in der Therapie der koronaren Herzkrankheit oder Herzinsuffizienz besitzen, scheinen Inhibitoren des ANP-Metabolismus insbesondere in der Kombination mit ACE-Hemmern den klinischen Verlauf positiv beeinflussen zu können.
APA, Harvard, Vancouver, ISO, and other styles
6

Oyston, P. C. F., M. A. Fox, S. J. Richards, and G. C. Clark. "Novel peptide therapeutics for treatment of infections." Journal of Medical Microbiology 58, no. 8 (August 1, 2009): 977–87. http://dx.doi.org/10.1099/jmm.0.011122-0.

Full text
Abstract:
As antibiotic resistance increases worldwide, there is an increasing pressure to develop novel classes of antimicrobial compounds to fight infectious disease. Peptide therapeutics represent a novel class of therapeutic agents. Some, such as cationic antimicrobial peptides and peptidoglycan recognition proteins, have been identified from studies of innate immune effector mechanisms, while others are completely novel compounds generated in biological systems. Currently, only selected cationic antimicrobial peptides have been licensed, and only for topical applications. However, research using new approaches to identify novel antimicrobial peptide therapeutics, and new approaches to delivery and improving stability, will result in an increased range of peptide therapeutics available in the clinic for broader applications.
APA, Harvard, Vancouver, ISO, and other styles
7

Smith, Josiah D., Leah N. Cardwell, David Porciani, Andrea Nolla, Brenna T. Cornelison, Megan C. Schulte, Fabio Gallazzi, Donald H. Burke, Mark A. Daniels, and Bret D. Ulery. "Therapeutic peptide delivery via aptamer-displaying, disulfide-linked peptide amphiphile micelles." Molecular Systems Design & Engineering 5, no. 1 (2020): 269–83. http://dx.doi.org/10.1039/c9me00092e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schwardt, Oliver, Christina Lamers, Clément Bechtler, and Daniel Ricklin. "Therapeutic Peptides as Emerging Options to Restore Misguided Host Defence and Homeostasis: From Teaching to Concept to Clinic." CHIMIA International Journal for Chemistry 75, no. 6 (June 30, 2021): 495–99. http://dx.doi.org/10.2533/chimia.2021.495.

Full text
Abstract:
Among the many molecular entities suitable for therapeutic use, peptides have emerged as a particularly attractive option for academic drug discovery and development. Their modular structure and extendibility, the availability of powerful and affordable screening platforms, and the relative ease-of-synthesis render therapeutic peptides highly approachable for teaching and research alike. With a strong focus on the therapeutic modulation of host defence pathways, including the complement and renin-angiotensin systems, the Molecular Pharmacy group at the University of Basel strongly relies on peptides to introduce students to practical aspects of modern drug design, to discover novel therapeutics for immune and inflammatory diseases, and to expand on options for the preclinical development of a promising drug class. Current projects reach from student-driven iterative design of peptidic angiotensin-converting enzyme inhibitors and the use of phage display technology to discover novel immune modulators to the development of protective peptide coatings for biomaterials and transplants and the structure-activity-relationship-guided optimization of therapeutic peptide drug candidates in late-stage clinical trials. Even at the current stage, peptides allow for a perfect circle between pharmaceutical research and education, and the recent spark of clinical applications for peptide-based drugs may only increase the value and relevance of this versatile drug class.
APA, Harvard, Vancouver, ISO, and other styles
9

Parthasarathy, Anutthaman, Sasikala K. Anandamma, and Karunakaran A. Kalesh. "The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations." Current Medicinal Chemistry 26, no. 13 (July 8, 2019): 2330–55. http://dx.doi.org/10.2174/0929867324666171012103559.

Full text
Abstract:
Peptide therapeutics has made tremendous progress in the past decade. Many of the inherent weaknesses of peptides which hampered their development as therapeutics are now more or less effectively tackled with recent scientific and technological advancements in integrated drug discovery settings. These include recent developments in synthetic organic chemistry, high-throughput recombinant production strategies, highresolution analytical methods, high-throughput screening options, ingenious drug delivery strategies and novel formulation preparations. Here, we will briefly describe the key methodologies and strategies used in the therapeutic peptide development processes with selected examples of the most recent developments in the field. The aim of this review is to highlight the viable options a medicinal chemist may consider in order to improve a specific pharmacological property of interest in a peptide lead entity and thereby rationally assess the therapeutic potential this class of molecules possesses while they are traditionally (and incorrectly) considered ‘undruggable’.
APA, Harvard, Vancouver, ISO, and other styles
10

Gopinatth, Varun, Rufa L. Mendez, Elaine Ballinger, and Jung Yeon Kwon. "Therapeutic Potential of Tuna Backbone Peptide and Its Analogs: An In Vitro and In Silico Study." Molecules 26, no. 7 (April 3, 2021): 2064. http://dx.doi.org/10.3390/molecules26072064.

Full text
Abstract:
Tuna backbone peptide (TBP) has been reported to exert potent inhibitory activity against lipid peroxidation in vitro. Since this bears relevant physiological implications, this study was undertaken to assess the impact of peptide modifications on its bioactivity and other therapeutic potential using in vitro and in silico approach. Some TBP analogs, despite lower purity than the parent peptide, exerted promising antioxidant activities in vitro demonstrated by ABTS radical scavenging assay and cellular antioxidant activity assay. In silico digestion of the peptides resulted in the generation of antioxidant, angiotensin-converting enzyme (ACE), and dipeptidyl peptidase-IV (DPPIV) inhibitory dipeptides. Using bioinformatics platforms, we found five stable TBP analogs that hold therapeutic potential with their predicted multifunctionality, stability, non-toxicity, and low bitterness intensity. This work shows how screening and prospecting for bioactive peptides can be improved with the use of in vitro and in silico approaches.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Therapeutic peptide"

1

Krysmann, Marta J. "Self-assembly of peptides and peptide based hybrids for therapeutic applications." Thesis, University of Reading, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.558793.

Full text
Abstract:
A rich gallery of novel systems based on the sequence KLVFF (namely KLVFF, FFKLVFF, AAKLVFF, AAKLVAA, βAβAKLVFF, KLVFF-PEG, FFKLVFF-PEG, AAKLVFF-PEG, AAKLVAA-PEG, FF-PEG, FFFF-PEG) was synthesized and characterized. For the first time structure-properties relationships of this class of materials were systematically explored, with emphasis on self-association properties in both bulk and solution. Such a comparative investigation, essentially absent from the literature, provides insights into the underlying mechanism of amyloid fibrogenesis, given that KL VFF has been identified as critical for amyloid fibril formation of the amyloid-β peptide. In this respect, this virtually unique, bottom-up approach contributes to the development of therapeutics for Alzheimer's disease. Despite the fact that all the peptides were found to organize into predominantly β-sheet conformations (in a variety of solvents and in bulk) they exhibit a versatile range of morphological features, such as fibrils, twisted assemblies of protofilaments, hollow tubes and single tapes. Interestingly, FFKLVFF was found to exhibit strong fibrillization properties, while helically twisted ribbons were obtained from βAβAKL VFF. The self-organization of KLVFF towards fibrillar symmetries gives rise, under certain conditions, to time-dependant hydrogels with potential for application in tissue engineering. Notably, only FFKLVFF-PEG and FFFF-PEG retain the β-sheet conformation of the peptide precursor, and they form fibrils bearing a peptidic core surrounded by a corona of PEG chains. At high volume fractions packing of the FFKLVFF-PEG fibrils leads to the evolution of nematic and hexagonal columnar phases. Owing to their inherent biocompatible character, those hybrids carry great promise to substitute a number of conventional polymers in applications such as tissue engineering, cell growth and drug delivery. In the solid state, the interplay between two competing factors, polymer crystallization and peptide fibrillization, was studied for several conjugates. Two distinct cases were identified; solidification of FFKL VFF-PEG controlled by peptide- peptide interactions, while KLVFF -PEG and AAKL V AA-PEG crystals reflected the characteristics of PEG spherulites.
APA, Harvard, Vancouver, ISO, and other styles
2

Roberts, David John. "Peptide based conjugates for therapeutic delivery applications." Thesis, University of Manchester, 2014. https://www.research.manchester.ac.uk/portal/en/theses/peptide-based-conjugates-for-therapeutic-delivery-applications(76cee616-80bf-4b31-89d1-63f699573e78).html.

Full text
Abstract:
The effect of peptide charge on the self-assembly and gelation behaviour of three octa-peptides: VEVKVEVK (VEK2), VKVKVEVK (VEK3) and VEVEVKVE (VEK1) has been investigated and characterised. The critical gelation concentration of each peptide was found to correlate with the charge modulus carried by the peptide and to be independent of the sign of the charge. Hydrogels formed were found to be transparent and stable when the peptide charge modulus is > 1. No differences in hydrogel structure or mechanical properties, as probed by TEM and SAXS and shear rheology, were found when the peptides were at the same concentration and carried the same charge modulus. These peptides were shown to form dense fibrillar network formed by β-sheet rich single fibre which lateral aggregation is controlled by the peptide charge modulus. The increase in fibre lateral aggregation with decreasing charge modulus was found to correlate with the increase in hydrogel mechanical properties, showing that fibre lateral aggregation pays a key role in controlling the mechanical properties of these hydrogels. The release profiles from VEK1 and VEK3 at pH 7 of two hydrophilic model drug molecules, namely napthol yellow (NY) and martius yellow (MY) was analysed using UV-Vis spectrophotometry. The incorporation of the guest molecules did not affect the self-assembly of the peptide at a molecular level but did affect the level of lateral fibre aggregation observed and therefore the mechanical properties of the hydrogels. The release of each of the model compounds was monitored over time and shown to be controlled by Fickian diffusion. The guest molecule diffusion rate D was dependent on the ratio between the overall effective charges carried by the peptide, i.e.: the fibrillar network, and the overall charges carried by the guest molecules but independent from the hydrogel concentration and mechanical properties, in the concentration and guest loading range investigated. This work shows that the rate of release of small drug molecules can be manipulated, not only by changing the charges on the guest molecules, but also by manipulating the charged state of the self-assembling peptide molecule and through it the charge state of the fribrillar network. Furthermore the VEK3 system was conjugated to a series of thermo-responsive synthetic polymers which imparted a significant change in mechanical properties, assembled structures and release profiles upon heating. Observed changes when above the polymers LCST include increased mechanical strength, fibre thickening and increased diffusion coeffcients. The synthesis, and subsequent characterisation, of these materials is the first time responsive hydrogels of OEGMA copolymers has been reported.
APA, Harvard, Vancouver, ISO, and other styles
3

Kilian, Gareth. "Development and testing of liposome encapsulated cyclic dipeptides." Thesis, Nelson Mandela Metropolitan University, 2011. http://hdl.handle.net/10948/1397.

Full text
Abstract:
Cyclic dipeptides have been well characterized for their multitude of biological activities, including antimicrobial and anticancer activities. Cyclo(His-Gly) and cyclo(His-Ala) have also recently been shown to possess significant anticancer activity against a range of cell lines, despite the limitations of these two molecules with respect to their physicochemical properties. Low Log P results in poor cell permeability which can often be problematic for drugs with intracellular mechanisms of action. It can also results in poor biodistribution, and theoretical Log P values for cyclo(His-Gly) and cyclo(His-Ala) were extremely low making them ideal candidates for inclusion into a nanoparticulate drug delivery system. The aim of this study was therefore to formulate and evaluate liposome-encapsulated cyclic dipeptides that increase the tumour-suppressive actions of the cyclic dipeptides, while showing a high degree of specificity for tumour cells. While liposomes are relatively simple to prepare, inter batch variation, low encapsulation and poor stability are often problematic in their production and this has lead to very few liposomal products on the market. This study aimed at using a comprehensive statistical methodology in optimizing liposome formulations encapsulating cyclo(His-Gly) and cyclo(His-Ala). Initial screening of potential factors was conducted using a 25-1 fractional factorial design. This design made use of two levels for each of the five factors and abbreviated the design to minimize runs. Although not much information is provided by these types of designs, the design was sufficient in identifying two critical factors that would be studies further in a more robust design. The two factors selected, based on the screening study, were cholesterol and stearylamine content. These two factors were then used in designing a response surface methodology (RSM) design making use of a central composite rotatable vii design (CCRD) at five levels (-1.5, -1, 0, 1, 1.5) for each factor in order to better understand the design space. Various factors influenced the measured responses of encapsulation efficiency, zeta potential, polydispersity index, cellular uptake and leakage, but most notable were the adverse effects of increasing stearylamine levels on encapsulations efficiency and cholesterol levels on leakage for both cyclo(His-Gly) and cyclo(His-Ala) liposomes. Optimized formulations were derived from the data and prepared. Fair correlation between the predicted and measured responses was obtained. The cytotoxic activity of the encapsulated cyclic dipeptides were assessed against HeLa and MCF-7 cells and found to have limited improvement in activity. However, modification of the polyethylene glycol (PEG) grafted to the liposome surface in order to target folate receptors showed good benefit in significantly decreasing the IC50 values recorded in all cells lines tested, particularly low folate HeLa cells with the lowest IC50 being recorded as 0.0962 mM for folate targeted cyclo(His-Ala). The results therefore indicate that hydrophilic cyclic dipeptides are ideal candidates for inclusion into targeted drug delivery systems such as liposomes. Key words: Liposomes, cyclo(His-Gly), cyclo(His-Ala), cyclic dipeptides, HeLa, MCF-7, folate receptors, factorial design, response surface methodology (RSM), central composite rotatable design (CCRD).
APA, Harvard, Vancouver, ISO, and other styles
4

Ngwa, Conelius. "Use of peptide nucleic acids as therapeutic agents." Thesis, Aston University, 2014. http://publications.aston.ac.uk/24385/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Qian, Yun. "Self-assembled Peptide Hydrogels for Therapeutic H2S Delivery." Diss., Virginia Tech, 2019. http://hdl.handle.net/10919/101094.

Full text
Abstract:
Hydrogen sulfide (H2S) is a gasotransmitter that is produced endogenously and freely permeates cell membranes. It plays important roles in many physiological pathways, and by regulating these pathways, it provides many therapeutic effects. For example, H2S dilates vascular vessels, promotes angiogenesis, and protects cells from oxidative stress. Due to its therapeutic effects, H2S has been used as a potential treatment for diseases like diabetes, ischemia-reperfusion injuries, lung diseases, ulcers and edemas, among others. To apply H2S for therapeutic applications, two challenges need to be addressed. The first challenge is the H2S donor, which not only provides H2S but must be stable enough to avoid side effects caused by overdose; and the second challenge is the delivery strategies, which transport the H2S to the target sites. A series of S-aroylthiooximes (SATOs), an H2S releasing compound, were synthesized and conjugated to peptide sequences to form H2S-releasing aromatic peptide amphiphile (APA) hydrogels. APAs formed nanofibers, which were stabilized by beta-sheets and aromatic stacking. The self-assembled structures were affected by the substituents on the aromatic rings of SATOs, leading to the formation of twisted nanofibers. After the addition of cysteine, H2S was released from the APAs with half-lives ranging from 13 min to 31 min. The electron-donating groups slowed down the H2S release rate, while the electron-withdrawing groups accelerated the release rate. Therefore, the release rates of H2S were controlled by electronic effects. When self-assembled structures were formed, the H2S release rate was slowed down even more, due to the difficulties in cysteine diffusion into the core of the structures. Antimicrobial effects were also discovered using the H2S releasing APA hydrogels. The H2S-releasing dipeptides S-FE and S-YE formed self-assembled twisted nanoribbons and nanotubes, respectively. The non H2S-releasing control oxime dipeptides C-FE and C-YE were also synthesized. The C-FE formed nanoribbons while the C-YE only showed non-specific aggregates. S-FE and S-YE released H2S with peaking times of about 41 and 39 min. Both the self-assembled structures and the release rates were affected by their packing differences. In vitro and ex vivo experiments with Staphylococcus aureus (Xen29), a commonly found bacterium on burn wounds, showed significant antimicrobial effects. APAs S-FE and C-FE eliminated Xen29 and inhibited the biofilm formation, while S-FE always showed better effects than C-FE. These antimicrobial H2S-releasing APA hydrogels provide a new approach to treat burn wound infections, and provide healing benefits due to the therapeutic effects of H2S.
Doctor of Philosophy
APA, Harvard, Vancouver, ISO, and other styles
6

Parker, Alan. "Development of peptide-targeted gene delivery systems." Thesis, University of Birmingham, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273727.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tasdemiroglu, Yagmur. "Small Therapeutic Peptides: In vitro pharmacokinetics of alpha-carboxyl terminus 11 peptide in rat plasma." Thesis, Virginia Tech, 2021. http://hdl.handle.net/10919/103639.

Full text
Abstract:
Cardiovascular diseases affect one third of the U.S. population and are the number one cause of death globally. Acute myocardial infarction is one of the most catastrophic cardiovascular diseases that permanently alters patient's lives. Small molecule drugs, surgery, medical devices and lifestyle changes are the current treatment methods that only address symptoms and fail to cure cardiovascular disorders. Small therapeutic peptides are emerging methods to treat diseases ranging from cancer to auto-immune disorders. Due to their nature, they are non-toxic, non-immunogenic, biocompatible and highly target specific. However, because of their small size and lack of tertiary structure, they have a very short half-life. Alpha-carboxyl terminus 11 peptide (αCT11) is a 9 amino acid long small peptide that has shown to promote left ventricular function recovery when mouse hearts are perfused with the peptide prior to an ischemia-reperfusion injury. This study investigates the in vitro pharmacokinetics of αCT11 in rat plasma in the presence of protease and phosphatase inhibitor cocktails to provide a method to delay its degradation and to understand the degradation pattern of the peptide in vitro. The effect of time, temperature, presence of inhibitors and sex are investigated. Results have shown that while sex does not have a significant effect on αCT11 degradation, time and temperature significantly promote its degradation. Utilization of inhibitors also leads to a pronounced delay in αCT11 degradation, as the amount of αCT11 remaining in plasma increases from almost undetectable to 15-16% upon introduction of inhibitors. These results indicate that αCT11 degradation can be delayed significantly when inhibitor cocktails are used, bringing αCT11 closer to being used in a clinical setting to address ischemia-reperfusion injuries.
Master of Science
Cardiovascular diseases affect millions of people worldwide and they are the number one cause of death globally. Current treatments for cardiovascular diseases mainly focus on alleviating symptoms as they arise and delaying the disease progression using small molecule drugs and lifestyle changes, which unfortunately are unable to cure the diseases permanently. Peptide treatment is a novel method to address various traditionally incurable diseases, such as auto-immune disorders and cancer. These therapeutic peptides are highly target specific, typically non-toxic and highly biocompatible since they are designed based on native proteins. Even though small therapeutic peptides have numerous benefits, a major drawback is that they have a very short half-life in plasma. Alpha-carboxyl terminus 11 peptide (αCT11) is a small peptide derived from alpha-carboxyl terminus 1 peptide (αCT1), which is in phase 2 clinical trials for chronic wound healing. It has been shown that αCT11 has cardioprotective effects when the heart is perfused with the peptide before an ischemia-reperfusion injury, such as a heart attack. This study investigates the in vitro pharmacokinetic properties of αCT11 in rat plasma with respect to time, temperature and sex with the aim to provide an effective method to allow αCT11 to remain in plasma for a longer period of time. As a method to delay αCT11 degradation due to plasma enzymes, enzyme inhibitors are used, which delayed the αCT11 breakdown significantly. The results have also shown that time and temperature are the main factors affecting αCT11 degradation in rat plasma in vitro while sex is not a significant factor. These results indicate that this small peptide can be protected in plasma with the use of inhibitors. This discovery can be a stepping stone to use αCT11 in clinical settings to help treat cardiovascular diseases.
APA, Harvard, Vancouver, ISO, and other styles
8

Barrios, Marrugo Kelly. "Therapeutic Peptide-Based Vaccination Strategies Against HPV-Induced Cancers." Scholar Commons, 2012. http://scholarcommons.usf.edu/etd/4283.

Full text
Abstract:
There is an urgent need for the development of an effective therapeutic vaccine against cancer caused by human papilloma virus (HPV). We focused on HPV-induced malignancies because of their high worldwide prevalence (e.g., cervical carcinoma and head & neck cancer). A successful therapeutic vaccine could prevent the 250 000 deaths/year worldwide and the 2.25 billion dollars that are expended in related care in the US. We used an HPV-induced mouse cancer model to test vaccines composed of a CD8 T cell peptide epitope administered with potent adjuvants designed to generate vast numbers of high avidity cytotoxic T lymphocytes specific for the HPV16-E7 antigen. One vaccination strategy (TriVax) consists of intravenous administration of synthetic peptide HPV16-E749-57 administered together with a Poly-IC (a TLR3 agonist) and anti-CD40 monoclonal antibody(αCD40 mAb) while the second more simple strategy (BiVax) comprises solely of peptide plus Poly-IC. We used an E7 peptide as antigen in the vaccination strategies because expression of the viral E6 and E7 proteins is required to maintain oncogenic phenotype and because normal cells do not express E6/E7, therefore a therapeutic vaccine targeting these proteins has several advantages: a) a strong immune response can be induced since immune tolerance to these foreign antigens does not exist and b) the strong immune response should not inflict damage to normal cells. TriVax and BiVax generate a high number of antigen specific CD8 T cells capable clear subcutaneous tumors and prevent recurrences, both vaccines are efficient through the i.v. and i.m. route. TriVax (prime-boost) clears tumor in 100% of mice while BiVax clears tumor in 50% of mice, this differential effect is due to the number of antigen specific CD8 T cells and increasing the number of booster shot makes BiVax as immunogenic and efficient in clearing tumors. In the absence of type-I IFN signaling (in IFNαΒR KO mice), TriVax is less effective in generating sufficient numbers of CD8 T cells that could be necessary for total disease eradication. We observed a significant anti-tumor effect of TriVax in the absence of interferon gamma, however the cytokine may play some role in the overall effectiveness of TriVax to completely reject the tumors. Immune responses produced by BiVax are highly dependent on the simultaneous administration of peptide and Poly-IC, on the peptide composition, vaccine formulation and route of administration. The magnitude of the response is dependent on the expression of the Poly-IC receptors TLR3 and melanoma differentiation-associated protein 5 (MDA5). Interestingly, the magnitude and duration of the CD8 T cell responses generated by peptide and Poly-IC mixtures does not rely on the presence of CD4 T cells, scavenger receptor-A (SR-A) or type-I IFN signals and was minimally affected by the absence of CD40 signaling. The present findings could facilitate the development of simple and effective subunit vaccines for diseases where CD8 T cells may hold a therapeutic benefit.
APA, Harvard, Vancouver, ISO, and other styles
9

Kwok, Hoi-shan, and 郭凱珊. "The comparison of biological properties of L- and D-enantiomeric antimicrobial peptides." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206507.

Full text
Abstract:
Antibiotics have been used widely for the treatment of bacterial infections for over half a century. However, the emergence of resistance to antibiotics has aroused public health concern, leading to the development of antimicrobial peptides (AMPs) as potential alternative therapeutic agents against bacterial infections. AMPs are naturally found in many species and have important roles in our innate immune defense systems. AMPs are usually cationic amphipathic peptides with membrane destabilizing property. They have a relatively broad spectrum of antimicrobial activity and pathogens are less likely to develop resistance against AMPs. The major challenge of using AMPs as therapeutic agents is their toxicity towards mammalian cells. The biological stability of AMPs to protease in human body is another concern. To address the latter problem, instead of the naturally occur L-enantiomers, Denantiomeric AMPs were introduced to enhance their stability. This study aimed to test the hypothesis that the D-enantiomeric AMPs are more resistant than the Lenantiomeric AMPs against proteolytic degradation. Three pairs of synthetic D-/LAMPs (D-LAO160-P13/LAO160-P12; D-LAO160-H/LAO160-H; and D-LAK-120-HP13/LAK-120-HP13) were employed to test for their stability when treated with trypsin, serum and gastric fluid, and the samples were analyzed by high performance liquid chromatography (HPLC). Generally, all the D-enantiomeric AMPs were found to be resistant towards proteolysis. Besides, to compare the cytotoxicity of D-/LAMPs, MTT and LDH assays of the D/L-LAK120-HP13 pair were carried out on two different cell lines, A549 cells (human lung adenocarcinoma epithelial cells) and RAW264.7 cells (mouse macrophage cells). Significant difference in cytotoxicity of D-LAK120-HP13 and LAK120-HP13 on RAW264.7 cells were obtained from MTT assay, but not in LDH assays or on A549 cells. Further analysis has to be done to validate the findings obtained from this research.
published_or_final_version
Pharmacology and Pharmacy
Master
Master of Medical Sciences
APA, Harvard, Vancouver, ISO, and other styles
10

Makhani, Kiran, and Kiran Makhani. "Mechanism of Action of ERBB Decoy Cancer Therapeutic Peptide SAH5." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/626139.

Full text
Abstract:
Breast cancer is the most prevalent type of cancer and second leading cause of death in women. Among others, the triple negative breast cancer (TNBC) is the most invasive as it has the highest recurrence and death rates with no targeted therapeutic available thus far. Epidermal Growth Factor Receptor (EGFR) is one of the important targets as more than fifty percent of the TNBC overexpress it but all the therapies designed against it have failed to show significant results. The juxtamembrane domain of EGFR has been explored comparatively recently and has been used to design a decoy peptide with the anticipation to affect the EGFR downstream functions. Previous research has shown it to cause cell death in cancer cells. This study is aimed towards deciphering the mechanism of action of the stapled form of this decoy peptide-SAH5. It presents evidence that the peptide leads to an immediate intracellular calcium release from the Inositol 1,4,5 triphosphate on the endoplasmic reticulum, an inhibition of which can rescue SAH5 induced cell death. The study also demonstrate that the peptide is able to increase the production of Reactive Oxygen Species (ROS) in mitochondria, part of which is triggered by the peptide-induced calcium release.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Therapeutic peptide"

1

Shahrokh, Zahra, Victoria Sluzky, Jeffrey L. Cleland, Steven J. Shire, and Theodore W. Randolph, eds. Therapeutic Protein and Peptide Formulation and Delivery. Washington, DC: American Chemical Society, 1997. http://dx.doi.org/10.1021/bk-1997-0675.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

NATO, Advanced Research Workshop on Advanced Drug Delivery Sytems for Peptides and Proteins (1986 Copenhagen Denmark). Delivery systems for peptide drugs. New York: Plenum in cooperation with NATO Scientific Affairs Division, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Peptide and protein delivery. London: Academic Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Anil, Sehgal. Peptide therapeutics: Applications in the treatment of human disease. Westborough, MA: D & MD Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Banga, Ajay K. Therapeutic peptides and proteins: Formulation, processing, and delivery systems. Lancaster, Pa: Technomic Pub., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Banga, Ajay K. Therapeutic peptides and proteins: Formulation, processing, and delivery systems. 2nd ed. Boca Raton, FL: CRC/Taylor & Francis, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Melanocortins: Multiple actions and therapeutic potential. New York: Springer Science+Business Media, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wolfgang, König. Peptide and protein hormones: Structure, regulation, activity :a reference manual. Weinheim: VCH, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sima, Anders A. F. Diabetes & C-peptide: Scientific and clinical aspects. New York: Humana, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Peptide drug delivery to the brain. New York: Raven Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Therapeutic peptide"

1

Dillon, Patrick M., and Craig L. Slingluff. "Peptide Vaccine: Overview." In Cancer Therapeutic Targets, 427–39. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-0717-2_145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dillon, Patrick M., and Craig L. Slingluff. "Peptide Vaccine: Overview." In Cancer Therapeutic Targets, 1–13. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-6613-0_145-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fomsgaard, Anders. "Therapeutic HIV Peptide Vaccine." In Methods in Molecular Biology, 351–57. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2999-3_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lax, E. Rodney, and Trishul Shah. "Chapter 6. Economic and Environmental Factors Affecting the Sustainability of Peptide Therapeutic Manufacturing." In Peptide Therapeutics, 151–93. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788016445-00151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kaliyaperumal, Arunan. "Chapter 3. Biological and Immunogenicity Evaluation Strategy for Therapeutic Peptides: Chemistry, Manufacturing and Controls Perspective." In Peptide Therapeutics, 69–96. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788016445-00069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kellenbach, Edwin, and Torgny Rundlöf. "Chapter 11. Determination of the Identity, Content and Purity of Therapeutic Peptides by NMR Spectroscopy." In Peptide Therapeutics, 381–420. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788016445-00381.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cremonesi, Marta, and Christiane Schuchardt. "Dosimetry for Peptide Receptor Radionuclide Therapy." In Therapeutic Nuclear Medicine, 769–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/174_2012_711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Melief, Cornelis J. M. "Peptide-Based Therapeutic Cancer Vaccines." In Oncoimmunology, 249–61. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-62431-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tomioka, Hideki, Akiko Tenma, and Makoto Sakaguchi. "Translational Research of Novel Peptide Vaccine." In Therapeutic Vaccines as Novel Immunotherapy, 67–71. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9628-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ryu, Jong Sang, A. Yeon Cho, Sang Won Seo, and Hosung Min. "Engineering Bioactive Peptide-Based Therapeutic Molecules." In Methods in Molecular Biology, 35–50. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-673-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Therapeutic peptide"

1

Qvit, Nir. "Engineered protein-protein interaction regulators for therapeutic applications." In 35th European Peptide Symposium. Prompt Scientific Publishing, 2018. http://dx.doi.org/10.17952/35eps.2018.047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kennedy, Andrew, James Cain, Cyf Ramos-Colon, and Daniel Martinez. "Therapeutic Peptides: Synthesis Optimization Using Parallel Automated SPPS." In 35th European Peptide Symposium. Prompt Scientific Publishing, 2018. http://dx.doi.org/10.17952/35eps.2018.090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Esteoulle, Lucie, Adrien Flahault, Cendrine Seguin, Sylvie Fournel, Benot Frisch, Xavier Iturrioz, Catherine Llorens-Cortes, and Dominique Bonnet. "Fluorocarbon-peptideconjugates (FPC): new concept to increase the metabolic stability of peptides for therapeutic applications." In 35th European Peptide Symposium. Prompt Scientific Publishing, 2018. http://dx.doi.org/10.17952/35eps.2018.265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Loureiro, Joana A., Manuel A. N. Coelho, Sandra Rocha, and Maria do Carmo Pereira. "Design of potential therapeutic peptides and carriers to inhibit amyloid β peptide aggregation." In 2012 IEEE 2nd Portuguese Meeting in Bioengineering (ENBENG). IEEE, 2012. http://dx.doi.org/10.1109/enbeng.2012.6331364.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Heyl, Deborah, Yeji Park, Jennifer Garvey, Rebecca Newman, and Yllka Vladaj. "Antimicrobial and Hemolytic Activity of Cysteine-Deleted Tachyplesin (CDT) Analogues in the Pursuit of Therapeutic Selectivity." In The 24th American Peptide Symposium. Prompt Scientific Publishing, 2015. http://dx.doi.org/10.17952/24aps.2015.181.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

O’Harte, Finbarr. "The design and assessment of the therapeutic potential of apelin-13 peptide mimetics for alleviating metabolic dysfunction in diabetes and obesity." In 35th European Peptide Symposium. Prompt Scientific Publishing, 2018. http://dx.doi.org/10.17952/35eps.2018.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rosca, Elena V., Marie-France Penet, Jacob E. Koskimaki, Niranjan B. Pandey, Zaver M. Bhujwalla, and Aleksander S. Popel. "Abstract 4267: Biomimetic anti-angiogenic peptide as therapeutic agent for breast cancer." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tao, Zhiyong, Daniel R. Studelska, James R. Wheatley, Eric A. Burge, Miranda Steele, Debbie Brame, Claire Brook, Alex Micka, Christie Belles, and Todd Osiek. "Synthesis and Analysis of a Lipid-PEG-Octreotate Conjugate for Targeted Delivery of Therapeutic Agents in Liposomes." In The Twenty-Third American and the Sixth International Peptide Symposium. Prompt Scientific Publishing, 2013. http://dx.doi.org/10.17952/23aps.2013.246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lee, David L., Hsiao-ling M. Chin, Christopher G. Knudsen, George L. Mayers, David S. Rose, Roy K. Skogstrom, Timothy Palzkill, et al. "Peptide-based scaffolds for in vivo immobilization and enzyme attachment in therapeutic applications." In Molecular and Nano Machines III, edited by Zouheir Sekkat and Takashige Omatsu. SPIE, 2020. http://dx.doi.org/10.1117/12.2566895.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Barbhuiya, Mustafa A., Adam C. Mirando, Brian W. Simons, Ghali Lemtiri-Chlieh, Jordan J. Green, Aleksander S. Popel, Niranjan B. Pandey, and Phuoc T. Tran. "Abstract 3201: Therapeutic potential of anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3201.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Therapeutic peptide"

1

Underhill, Charles B., and Lurong Zhang. Therapeutic Effect of Targeted Hyaluronan Binding Peptide on Neurofibromatosis. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada431642.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Lurong. Therapeutic Effect of Targeted Hyaluronan Binding Peptide on Neurofibromatosis. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada412140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Underhill, Charles B., and Lurong Zhang. Therapeutic Effect on Targeted Hyaluronan Binding Peptide on Neurofibromatosis. Fort Belvoir, VA: Defense Technical Information Center, September 2005. http://dx.doi.org/10.21236/ada507414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Lurong. Therapeutic Effect of Targeted Hyaluronan Binding Peptide on Neurofibromatosis. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada420850.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dolan, Brian P. A Novel Therapeutic Vaccine for Metastatic Mammary Carcinoma: Focusing MHC/Peptide Complexes to Lipid Rafts. Fort Belvoir, VA: Defense Technical Information Center, May 2005. http://dx.doi.org/10.21236/ada437901.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pasquanlini, Renata. Tumor-Targeting Peptides for Therapeutic Gene Delivery (97breast). Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada390775.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mierswa, S. C., T. H. Lee, and M. C. Yung. Developing an engineered therapeutic microbe to release antimicrobial peptides (AMPs). Office of Scientific and Technical Information (OSTI), August 2019. http://dx.doi.org/10.2172/1558856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yung, M. C. Engineering a therapeutic microbe for site-of-infection delivery of encapsulated antimicrobial peptides (AMPs). Office of Scientific and Technical Information (OSTI), October 2019. http://dx.doi.org/10.2172/1573149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Shaomeng. Design and Evaluation of Cyclized Small Peptides Derived from Her-2 as a Novel Therapeutic Strategy for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada437696.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Therapeutic peptide' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography